Mandate

Vinge advises Embracer in connection with the financing of its intended acquisition of Asmodee

December 16, 2021 Banking and Finance

Embracer Group AB (publ) has entered into exclusive negotiations to acquire the Asmodee group from amongst others funds advised or managed by PAI Partners SAS. The acquisition is subject to completion of the consultation of the relevant works council and exercise by the shareholders of Asmodee of their sell option.

Vinge has advised Embracer in connection with the signing of a new SEK 18 billion facilities agreement with SEB, Nordea and Swedbank for the purpose of, amongst other things, financing the acquisition.

Embracer Group is the parent company of businesses developing and publishing PC, console and mobile games for the global games market. With its head office based in Karlstad, Sweden, Embracer Group has a global presence through eight operative groups with 86 internal game development studios, and is engaging more than 9,000 employees and contracted employees in more than 40 countries.

Vinges consisted of Louise Brorsson Salomon, Lionardo Ojeda and Felix Möller.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026